2015-340B & Prime Vendor Program Update



Similar documents
10/1/2013. Objectives. 340B Drug Pricing Program; Transitioning from Access to Integrity. 340B Stats, Arkansas. 340B Participating Entities, AR

Federal 340B Drug Pricing Program

340B Drug Pricing Program January 15, 2015

340B Drug Discount Program Overview and Emerging Issues

Keep Your Savings: 340B Audits and Ensuring Compliance

4/3/2015 WHAT IS 340B? DISCLOSURE. No conflicts of interest to disclose

340B Drug Pricing Program: Overview and Recent Developments

CPAs and ADVISORS. experience access // 340B QUALIFICATIONS, BENEFITS AND CURRENT FOCUS

HRSA Pharmacy Services Support Center: The 340B Access Resource

340B Drug Discount Program Improving Compliance to Protect Savings and Be Audit Ready. Suzanne Herzog Founding Director Rx X Consulting

The 340B Drug Pricing Program: The Basics

The 340B Drug Pricing Program. Ariel Winter and Daniel Zabinski November 6, 2014

340B: ARE WE MONITORING COMPLIANCE EFFECTIVELY AND EFFICIENTLY

Finally... maybe? The Long Awaited 340B Mega Guidance. Georgia Healthcare Financial Management Association. October 2015

340B Drug Pricing Program

The 340B Drug Discount Program Overview, Compliance Issues and Interplay with Medicare and Medicaid

XXXXXXXFUNDAMENTALS An Essential Guide for Health System Executive Management

340B UNIVERSITY Las Vegas Edition. May 31, 2014

340B Drug Discount Program Identifying risks and internal audit focus areas

7/16/ th Annual 340B Coalition Conference July 19, 2010 Washington, DC. Safety Net Hospitals for Pharmaceutical Access

The 3 Keys to Success in Your 340B Program. Rob Nahoopii, PharmD, MS, BCPS CEO Turnkey Pharmacy Solutions A 340B Management Company

340B Drug Pricing Program: Recent Developments and Compliance Update

Maximizing the 340B Drug Discount Program: A Webinar for Finance Executives in 340B Hospitals Webinar

The 340B Drug Pricing Program: The Basics INTEGRITY ACCESS VALUE 1

340B UNIVERSITY San Francisco Edition. February 3-4, 2015

The 340B Program: New Developments and New Opportunities for CAHs and Others. Todd Nova Hall Render

Structuring 340B Contract Pharmacy Arrangements: Meeting Legal and Regulatory Requirements

Overview of the 340B Drug Pricing Program

340B Compliance: I sure wish I d known that!

Legal Alert. Long-Awaited 340B Program Guidance Now Available for Comments: What Stakeholders Need to Know. Authors

340B University Page 1 Split-Billing Software Considerations Checklist

340B Compliance Self-Assessment: Self-Audit Process Page 1 A Sample Self-Audit Process for Community Health Centers

340B Drug Pricing Program 340B Contract Pharmacy

DSH Litigation and 340B Program Update: What Participating Hospitals Need to Know and What They Should Be Doing

The PHS 340B Drug Pricing Program

Implementing a System-wide 340B Program

Ensuring Integrity in use of 340B pricing: Responsibility, Compliance, Accountability

GAO DRUG PRICING. Manufacturer Discounts in the 340B Program Offer Benefits, but Federal Oversight Needs Improvement

STATEMENT OF DIANA ESPINOSA DEPUTY ADMINISTRATOR, HEALTH RESOURCES AND SERVICES ADMINISTRATION BEFORE THE

340B PROGRAM. Scrutiny & Uncertainty Increase the Need for Compliance

GROWTH OF THE 340B PROGRAM: PAST TRENDS, FUTURE PROJECTIONS

NAMD WORKING PAPER SERIES. Medicaid and the 340B Program: Alignment and Modernization Opportunities

The Pharmacy 340B Program- Compliance & Internal Audit Strategies. for Covered Entities. Matthew D. Vogelien Huron Healthcare

Challenges and Opportunities

October 27, Attention: RIN 0906-AB08. RE: 340B Drug Pricing Program Omnibus Guidance. Dear Captain Pedley:

SUMMARY: The Health Resources and Services Administration (HRSA) administers section

340B DRUG DISCOUNT PROGRAM OMNIBUS GUIDANCE. Presented by the American Bar Association Health Law Section and Center for Professional Development

340B University Page 1 340B Manager and Coordinator Job Description Template

PHARMACY CARE FQHCs AND 340B PROGRAM

Hemophilia Treatment Center Manual for Participating in the Drug Pricing Program Established by Section 340B of the Public Health Service Act

The 340B Program: Today and Beyond

AHLA. Transmitting PHI by (page 16) 340B Program Covered Entity Audits (page 24) FCA Cases Involving Swapping Schemes (page 42)

MEDICARE PART B DRUGS. Action Needed to Reduce Financial Incentives to Prescribe 340B Drugs at Participating Hospitals

340B Mega Guidance: Implications for Essential Hospitals Sarah Mutinsky and Barbara Eyman Washington Counsel, America s Essential Hospitals Eyman

The 340B Drug Pricing Program: The Basics

340B and the Pharmacy Wholesaler s Role

OPA DATABASE GUIDE PUBLIC USERS - RECERTIFICATION FOR AUGUST 2013 VERSION 5.2.1

TEXAS VENDOR DRUG PROGRAM PHARMACY PROVIDER PROCEDURE MANUAL

340B Omnibus Guidance Would Significantly Narrow the Pool of Eligible Patients

Alabama Department of Public Health Drug Purchasing Programs: 340B and MMCAP. Alabama Department of Public Health 8/20/2012

HRSA Issues Proposed Omnibus 340B Guidance

(RIN) 0906-AB08; 340-B

THE 340B DRUG DISCOUNT PROGRAM A Review and Analysis of the 340B Program

340B Policy Landscape

Medicaid and 340B. Presentation to: GHA 340B Day Presented by: Linda Wiant, Pharm.D. Pharmacy Director. Date:

340B Benefits Some, Not Others

Sec. 340B PUBLIC HEALTH SERVICE ACT

Part B drug payment policy issues

THE 340B DRUG DISCOUNT PROGRAM A Review and Analysis of the 340B Program

UPDATES ON 340B Where do we go from here?

The Federal 340B Drug Discount Program: A Primer

Is your organization 340B equipped? Understanding Contract Pharmacy arrangements

HRSA Publishes 340B Drug Pricing Program Omnibus Guidance Notice: Significant Policy Ramifications Should Trigger Public Comment

Federal 340B Drug Discount Program: Compliance Issues

Transcription:

2015-340B & Prime Vendor Program Update Christopher A. Hatwig, R.Ph., MS, FASHP President, Apexus

340B Sales by Entity Types Percentage of Total Apexus Participant Sales 90.00% 80.00% 70.00% 60.00% 50.00% % of Total Sales Hospital 81.14% 40.00% 13% 30.00% 20.00% 10.00% 0.00% 0.40% 1.79% Free-Standing Cancer (CAN) Children's Hospitals (PED) 3.29% Rural Hospitals (CAH/RRC/SCH) DSH 87% 7.00% 6.00% 5.00% 4.00% % of Total Sales Non-Hospital 5.83% 5.85% 3.00% Hospital Non-Hospital 2.00% 1.00% 0.00% 0.11% 0.56% 1.03% HM STD/TB Title X (FP) Ryan White (HV) FQHC 2

GPO Prohibition Established in original 340B legislation in 1992 Prevents GPO use for Covered Outpatient Drugs Applies to Disproportionate Share Children s Hospitals Free Standing Cancer Hospitals Such hospitals...will not participate in a group purchasing organization or group purchasing arrangement for covered outpatient drugs as of the date of this listing on the OPA website. Release clarifying OPA Policy February 23, 2013 letter of GPO Prohibition enforcement by HRSA Hospitals must be compliant effective August 7, 2013 3

GPO Prohibition Clarification Purchase Flow for Most Hospitals Non-compliant State Compliant State 340B All Other (Default to GPO) 340B Registered Hospital Inpatient or Non-Covered Drugs (GPO) 340B All Other Out- Patient Covered Drugs (Default to Non-GPO Account) 4

How does the Medicaid Exclusion File work? 340B Discount Entity State Medicaid Exclusion File Medicaid Rebate Manufacturer 2014 Apexus. Reproduction without permission is prohibited. 5

Medicaid Update Simple goal prevent duplicate discounts Challenges for a solution coordination of HRSA, states and CMS Marketplace alternatives to the HRSA Medicaid Exclusion File (ex. NCPDP standards, UD modifiers) State policy is variable and sometimes not informed States refuse to use the Medicaid Exclusion File States require entities to share any 340B refund payments from manufacturers (from years ago) States require entities to self-audit for use of non-covered outpatient drugs in the past Apexus has contributed by providing education to states 340B U for State Medicaid Pharmacy Directors (August 2014) Discussions regarding fair reimbursement models 6

HRSA Activity Expected in 2015 Increase the number of audits Covered entity audits focus on diversion, duplicate discounts, and GPO prohibition (for DSH, CAN and PED) Manufacturer audits (OIG report pending) Publish Mega-guidance (summer 2015) Regulations Civil-monetary penalties Administrative dispute resolution Drug pricing Focus on Medicaid Exclusion File/policy (modernize) Continue working toward publishing 340B ceiling prices

HRSA Audits by the Numbers Number of covered entities audited FY 2012 FY 2013 FY 2014 FY 2015* (As of 1/13/15) 51 94 99 33 Outpatient facilities/sub-grantees 410 718 1,476 698 Contract pharmacies 860 1937 4,028 1688 Number of finalized reports 51 75 18 0

Orphan Drug Update Chaotic marketplace Wholesalers are at financial risk between the manufacturers and hospitals; some are more conservative and have decided to block all sales and manage the manufacturers products that agreed to sell as an exception HRSA wrote letters of inquiry to all companies for which complaints of not offering 340B prices on orphan drugs were received Of the 27 companies that had orphan drugs, 14 are offering 340B pricing and 13 are not Feb 4 th - HRSA posted the names of the manufacturers not offering 340B pricing on their website

HRSA S 340B PRIME VENDOR PROGRAM (340B PVP) APEXUS

Apexus Programs Supporting HRSA and 340B Stakeholders CONTRACTING ASSISTANCE EDUCATION Brand and Generic Rx Pricing Wholesaler Networks Apexus Answers Call Center 340B University & 340B OnDemand

Benefits of the 340B PVP to Covered Entities Sub-340B and Sub-WAC pricing on outpatient pharmaceuticals Discounts on value added products, services, and supplies Apexus Manufacturer Refund Service Pricing transparency Distribution solutions 340B Education and compliance support

Benefits of 340B PVP to Pharmaceutical Manufacturers Aggregator of outpatient purchasing in the 340B space Works closely with HRSA under an exclusive agreement; successful track record (10 years) Understands government rules, drug pricing, contracting, and the unique needs of both covered entities and manufacturers Extend full price protections on all sales to participating covered entities Provides a single point of entry into a complex market for outpatient pharmaceuticals

Prime Vendor Pricing Comparison Adapted from a slide by Safety Net Hospitals for Pharmaceutical Access Source: Data derived from Prices for Brand-Name Drugs Under Selected Federal Programs, Congressional Budget Office

Minimizing WAC Expense Apexus team is working to identify and share leading practices used by entities to minimize WAC expense Large variances among participants Analyzing data by split-billing vendor Strategies: minimizing lost charges, determining a policy for expired medications, evaluating Medicaid carve-out status, and identifying GPO only areas Apexus contracting team has worked to provide value by contracting for sub-wac pricing, in 2014 7,508 products on non-gpo/wac contracts

Look Familiar?

Assistance/Education EDUCATION APEXUS ANSWERS Developed to support integrity provisions Inaugurated September 2011 2014 Graduates: > 2,000 Sessions in 2015: 10+ Diversity of stakeholders 340BUniversity@340bpvp.com Critical HRSA need Launched: October 1, 2012 HRSA-approved answers Hours of operation: Mon-Fri 8:00 AM 5:00 PM CST 888.340.2787 ApexusAnswers@340bpvp.com

Apexus Answers: Hot Topics Mega-guidance, summer 2015 GPO Prohibition: Split-billing software configuration/malfunction, minimizing WAC spend Defining material breach of non-compliance 340B Contract pharmacy attempting to manage repayment/credits on behalf of entity (manufacturer wonders Why is this pharmacy mailing me a check? ) Instead of repayment or credit-rebill, some entities opt to adjust future purchasing to correct past mistakes Interpretation of covered outpatient drugs Inquiries regarding orphan drugs 19

340B University: Top Compliance- Focused Tools 1. 340B independent audit RFP checklist (new) 2. Split-billing tool (new) 3. Self-disclosure tool 4. Sample self-audit guides 5. Sample SOPs Tools: https://www.340bpvp.com/340b-university/tools-and-resources/ 20

Level 1 Level 2 Level 3 Apexus Certificate Program -Curriculum Structure & Audience Open Course Application Certificate Master Certificate Overview of foundational 340B knowledge Application in 340B operational integrity Policy to practice compliance interpretation 21

Focus for 2015 Grow sub-340b portfolio savings value Continue to build out portfolio of sub-wac pricing to minimize WAC expenditures and support participants in optimizing Maintain high customer satisfaction and call center ratings Advance manufacturer refund program through strategic partnerships Implement specialty pharmacy solution to support participants access to product and 340B pricing Expand education offerings for advanced training and certification

ENVIRONMENTAL SCAN, ONGOING CHALLENGES, & PREDICTIONS 23

340B Environmental Scan Manufacturers support opening 340B statute, scrutinizing hospital eligibility criteria Republican control of Senate and retirement of 340B-supportive legislators change environment for 340B Orphan drug lawsuit is expected to have final briefs due in March 2015 GAO and OIG have 340B reports underway (Medicare) Reimbursement challenges with payers and Medicaid will increase

340B Intent To permit covered entities to stretch scarce Federal resources as far as possible, reaching more eligible patients and providing more comprehensive services. H.R. Rep. No. 102-384(II), at 12 (1992)

Ongoing Points of Dispute Is the intent of 340B for the entity, the patient, or both? Should hospital eligibility criteria (DSH %) be revisited? Do contract pharmacies need to be limited in some way? Should program be limited to the uninsured? What should be done to modernize the HRSA Medicaid Exclusion File? Does HRSA have the authority to issue regulations?

Questions?

Contact Information Apexus Answers: M-F 8:00-5:00 PM CT Email: ApexusAnswers@340bpvp.com Website: www.340bpvp.com